Cytokinetics to Participate in Upcoming Investor Conferences
November 07 2018 - 04:00PM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that
Robert I. Blum, President and Chief Executive Officer, is scheduled
to present a corporate update at the Credit Suisse 27th Annual
Healthcare Conference on Tuesday, November 13, 2018 at 10:20 AM MT
at The Phoenician in Scottsdale, AZ, and to participate in a
Fireside Chat at the 30th Annual Piper Jaffray Healthcare
Conference on Tuesday, November 27, 2018 at 10:00 am ET at the
Lotte New York Palace in New York. Additionally, members of
Cytokinetics’ senior management team will also participate in the
Global Mizuho Investor Conference on December 3-4, 2018 at the
Lotte New York Palace in New York.
Interested parties may access the live webcast
of these presentations by visiting the Investors & Media
section of the Cytokinetics website at www.cytokinetics.com. The
webcast replay of each presentation will be archived on the
Presentations page within the Investors & Media section of
Cytokinetics’ website for 90 days following the conclusion of the
event.
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators and best-in-class
muscle inhibitors as potential treatments for debilitating diseases
in which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating
with Amgen Inc. ("Amgen") to develop omecamtiv mecarbil,
a novel cardiac muscle activator. Omecamtiv mecarbil is
the subject of GALACTIC-HF, an international Phase 3 clinical trial
in patients with heart failure. Amgen holds an exclusive
worldwide license to develop and commercialize omecamtiv
mecarbil with a sublicense held by Servier for
commercialization in Europe and certain other
countries. Cytokinetics is also collaborating
with Amgen to develop AMG 594, a first-in-class cardiac
troponin activator, discovered under the companies' joint research
program. Further development of AMG 594 is subject to the
collaboration agreement
between Amgen and Cytokinetics. Cytokinetics is
collaborating with Astellas Pharma Inc. ("Astellas") to
develop reldesemtiv, a fast skeletal muscle troponin activator
(FSTA). Reldesemtiv has been granted orphan drug
designation by the FDA for the potential treatment of
spinal muscular atrophy. Reldesemtiv was the subject of a
positive Phase 2 clinical study in patients with spinal muscular
atrophy which showed increases in measures of endurance and stamina
consistent with the mechanism of action. Reldesemtiv is
currently the subject of a Phase 2 clinical trial in patients with
amyotrophic lateral sclerosis. Cytokinetics is also advancing
CK-601, a next-generation FSTA into IND-enabling studies under the
collaboration with Astellas. Astellas holds an exclusive worldwide
license to develop and commercialize reldesemtiv. Licenses
held by Amgen and Astellas are subject to specified
co-development and co-commercialization rights
of Cytokinetics. Cytokinetics recently filed an IND
for CK-274, a novel cardiac myosin inhibitor that company
scientists discovered independent of its
collaborations. Cytokinetics continues its 20-year
history of innovation with three new muscle biology directed
compounds advancing from research to development in 2018. For
additional information about Cytokinetics,
visit www.cytokinetics.com.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating
to Cytokinetics' and its partners' research and
development activities of Cytokinetics’ product candidates. Such
statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to the risks related
to Cytokinetics' business outlined
in Cytokinetics' filings with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and Cytokinetics' actual results
of operations, financial condition and liquidity, and the
development of the industry in which it operates, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements
that Cytokinetics makes in this press release speak only
as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:Cytokinetics
Diane Weiser
Vice President, Corporate Communications,
Investor Relations(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2023 to Mar 2024